Astragaloside IV

Astragaloside IV is a triterpene saponin extracted from Astragalus membranaceus root that demonstrates anti-inflammatory and antioxidant properties. It works primarily by inhibiting NF-κB signaling pathways and activating Nrf2-mediated antioxidant responses.

Origin & History

Astragaloside IV (AS-IV) is a pentacyclic triterpenoid saponin isolated from the dried root of Astragalus membranaceus, a traditional Chinese medicinal herb. It is extracted using n-butanol followed by HPLC purification, with the Chinese Pharmacopoeia requiring a minimum content of 0.080% AS-IV in quality Astragali Radix preparations.

Historical & Cultural Context

Astragaloside IV is the primary active constituent in Astragalus membranaceus, used in Traditional Chinese Medicine for centuries to tonify qi and treat fatigue, immune deficiency, and cardiovascular issues. Modern pharmacological research on its anti-tumor, anti-inflammatory, and antioxidant properties aligns with these traditional applications.

Health Benefits

• Anti-inflammatory effects through NF-κB inhibition and TLR4/MyD88 pathway suppression (preclinical evidence only)
• Antioxidant activity via reactive oxygen species scavenging and Nrf2 activation (in vitro studies)
• Potential anticancer properties through cell cycle regulation and apoptosis modulation at 50-100 ng/mL (cell culture models)
• Cardioprotective effects suggested through multiple pathway modulation (animal studies only)
• Immune system support aligned with traditional qi-tonifying applications (traditional use, lacks clinical validation)

How It Works

Astragaloside IV suppresses inflammatory responses by blocking NF-κB nuclear translocation and inhibiting the TLR4/MyD88 signaling cascade. It enhances cellular antioxidant defenses through Nrf2 pathway activation, increasing expression of antioxidant enzymes like HO-1 and NQO1. The compound also modulates cell cycle proteins and promotes apoptosis in abnormal cells through p53 and caspase pathway activation.

Scientific Research

The research dossier reveals a critical gap: no human clinical trials, RCTs, or meta-analyses for Astragaloside IV were identified. All available evidence comes from preclinical studies using in vitro and animal models, with researchers calling for human trials to validate observed anticancer, anti-inflammatory, and cardioprotective effects.

Clinical Summary

Current evidence for astragaloside IV is primarily limited to preclinical studies and in vitro research. Animal studies have shown anti-inflammatory effects at doses of 10-50 mg/kg, with significant reductions in inflammatory markers like TNF-α and IL-6. Antioxidant activity has been demonstrated in cell culture studies using concentrations of 1-100 μM. No human clinical trials have been published to date, making clinical efficacy and optimal dosing unclear.

Nutritional Profile

Astragaloside IV is a purified triterpenoid saponin compound (cycloartane-type), not a whole food ingredient, therefore it contains no meaningful macronutrients, dietary fiber, vitamins, or minerals in its isolated form. Molecular weight: 784.98 g/mol (C41H68O14). It is the primary bioactive glycoside extracted from Astragalus membranaceus root, typically present at 0.01–0.04% by dry weight in raw root material. As an isolated compound, it is administered in concentrations ranging from 25–100 mg/kg in preclinical animal models and at 50–100 ng/mL in cell culture studies. Bioavailability is notably poor when taken orally: absolute oral bioavailability is estimated at approximately 2.2–3.8% in rodent models due to low intestinal permeability and extensive first-pass metabolism, with a Tmax of approximately 0.5–1 hour and half-life of roughly 2–4 hours. Gut microbiota partially hydrolyze the glycoside moieties, producing aglycone metabolites (cycloastragenol) which may exhibit enhanced membrane permeability. Lipophilicity is low-to-moderate (logP approximately 0.3), limiting passive diffusion. Nanoparticle and phospholipid complex formulations have been shown in preclinical studies to increase bioavailability by 3–5 fold. No caloric, protein, fat, or carbohydrate content is nutritionally relevant in supplemental doses (typically 5–50 mg per dose in commercial preparations).

Preparation & Dosage

No clinically studied dosage ranges for humans have been established. Preclinical studies use concentrations of 50-100 ng/mL in cell culture models, but these cannot be extrapolated to human dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Astragalus polysaccharides, Ginsenosides, Quercetin, Resveratrol, Cordyceps

Safety & Interactions

Safety data for astragaloside IV in humans is limited due to lack of clinical trials. Animal studies suggest good tolerability at therapeutic doses, though higher concentrations may cause gastrointestinal upset. No specific drug interactions have been documented, but theoretical interactions may exist with immunosuppressive medications due to immune-modulating effects. Safety during pregnancy and lactation is unknown, and use should be avoided in these populations.